Real World Adoption of FDA-approved Peanut Oral Immunotherapy with Palforzia

Authors

Sara Patrawala, University of Rochester School of Medicine and Dentistry, Rochester NY.
Allison Ramsey, Rochester Regional HealthFollow
Peter Capucilli, Rochester Regional HealthFollow
Linh-An Tuong, Rochester Regional HealthFollow
Karthik Vadamalai, Mercy Hospital, Springfield, MO.
S Shahzad Mustafa, Rochester Regional HealthFollow

Department

Allergy and Immunology

Document Type

Article

Publication Title

Journal of Allergy and Clinical Immunology: In Practice

Abstract

Clinical Implications: This is the first study to evaluate real-world uptake of FDA-approved POIT, revealing that approximately 10% of peanut-allergic individuals and families chose to pursue therapy, whereas the majority declined due to concerns over time commitment and adverse effects.

First Page

1120

Last Page

1122

DOI

10.1016/j.jaip.2021.12.022

Volume

10

Issue

4

Publication Date

4-1-2022

Comments

Presented as a poster at the American Academy of Allergy, Asthma, and Immunology Virtual Annual Meeting, 2021.

PubMed ID

34979334

Recommended Citation

Patrawala, S., Ramsey, A., Capucilli, P., Tuong, L., Vadamalai, K., & Mustafa, S. S. (2022). Real World Adoption of FDA-approved Peanut Oral Immunotherapy with Palforzia. Journal of Allergy and Clinical Immunology: In Practice, 10 (4), 1120-1122. https://doi.org/10.1016/j.jaip.2021.12.022